V

Viking Therapeutics
D

VKTX

38.050
USD
1.08
(2.92%)
Post Trading·37.900USD-0.150(-0.39%)
حجم التداول
155,762
الربح لكل سهم
-5
العائد الربحي
-
P/E
-9
حجم السوق
4,417,819,716
أصول ذات صلة المقالات
المزيد

العنوان: Viking Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.